Data presented at the EuroPCR conference suggest transcatheter aortic valve replacement with the CoreValve system from Medtronic continues to offer clinical benefits at one year in "real-world" cases. Addressing concerns about aortic regurgitation, researcher Dr. Stephen Brecker said, "We don't think there is a significant improvement in aortic regurgitation. What the data refute is that it is getting any worse." SCAI Past President Dr. Larry Dean called that finding "hypothesis generating" and said results overall were "remarkable for a high procedure success." A second study accounting for cost and quality of life metrics found TAVR cost-effective.

Related Summaries